These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 18040615)

  • 41. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide.
    Fiorica F; Berretta M; Colosimo C; Stefanelli A; Ursino S; Zanet E; Palmucci T; Maugeri D; Malaguarnera M; Palmucci S; Grasso M; Tirelli U; Cartei F
    Arch Gerontol Geriatr; 2010; 51(1):31-5. PubMed ID: 19628288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
    Levin VA; Maor MH; Thall PF; Yung WK; Bruner J; Sawaya R; Kyritsis AP; Leeds N; Woo S; Rodriguez L
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):357-64. PubMed ID: 7673023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extent of surgical resection and adjuvant temozolomide improves survival in pediatric GBM: a single center experience.
    Gupta S; Mallick S; Benson R; Haresh KP; Julka PK; Rath GK
    Childs Nerv Syst; 2017 Jun; 33(6):951-956. PubMed ID: 28424876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
    Kimple RJ; Grabowski S; Papez M; Collichio F; Ewend MG; Morris DE
    Am J Clin Oncol; 2010 Jun; 33(3):265-70. PubMed ID: 19823072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
    N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.
    Uto M; Mizowaki T; Ogura K; Arakawa Y; Mineharu Y; Miyamoto S; Hiraoka M
    Int J Clin Oncol; 2016 Dec; 21(6):1023-1029. PubMed ID: 27384182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
    Mineo JF; Bordron A; Baroncini M; Ramirez C; Maurage CA; Blond S; Dam-Hieu P
    Acta Neurochir (Wien); 2007 Mar; 149(3):245-52; discussion 252-3. PubMed ID: 17273889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
    Behm T; Horowski A; Schneider S; Bock HC; Mielke D; Rohde V; Stockhammer F
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2142-6. PubMed ID: 23993314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
    Malkoun N; Fotso MJ; Cartier L; Forest F; Auberdiac P; Chargari C; Thorin J; Pacaut C; Peoc'h M; Nuti C; Schmitt T; Magné N
    Cancer Radiother; 2011 Jun; 15(3):202-7. PubMed ID: 21450506
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
    Balducci M; Chiesa S; Diletto B; D'Agostino GR; Mangiola A; Manfrida S; Mantini G; Albanese A; Fiorentino A; Frascino V; De Bari B; Micciche' F; De Rose F; Morganti AG; Anile C; Valentini V
    Neuro Oncol; 2012 Jan; 14(1):79-86. PubMed ID: 21993440
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcomes in children with glioblastoma.
    Song KS; Phi JH; Cho BK; Wang KC; Lee JY; Kim DG; Kim IH; Ahn HS; Park SH; Kim SK
    J Neurosurg Pediatr; 2010 Aug; 6(2):145-9. PubMed ID: 20672935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
    Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A
    J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
    Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study.
    Szczepanek D; Marchel A; Moskała M; Krupa M; Kunert P; Trojanowski T
    Neurol Neurochir Pol; 2013; 47(2):101-8. PubMed ID: 23649997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
    Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
    J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
    Lipani JD; Jackson PS; Soltys SG; Sato K; Adler JR
    Technol Cancer Res Treat; 2008 Jun; 7(3):249-55. PubMed ID: 18473497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.